AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Company Overview - AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex, ABP-450, for various therapeutic indications, initially targeting the neurosciences market [2] - ABP-450 is the same botulinum toxin complex marketed for cosmetic use under the name Jeuveau by Evolus [2] - The product is manufactured by Daewoong in compliance with current Good Manufacturing Practice (cGMP) and is approved by the U.S. FDA, Health Canada, and the European Medicines Agency [2] - AEON holds exclusive development and distribution rights for therapeutic indications of ABP-450 in the U.S., Canada, the EU, the UK, and other international territories [2] Upcoming Events - Marc Forth, AEON's President and CEO, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 1:30 PM ET in New York [1] - Mr. Forth will also engage in one-on-one meetings with institutional investors during the conference [1]